Core Viewpoint - The approval of ICP-538 by the National Medical Products Administration (NMPA) marks a significant milestone for the company as it is the first VAV1 molecular glue degrader developed in China and the second globally to enter clinical research [1] Group 1: Product Development - ICP-538 is a novel oral, highly efficient, and selectively targeted VAV1 molecular glue degrader [1] - VAV1 is a critical protein downstream of T cell and B cell receptors, which is essential for developing treatments for various difficult-to-treat autoimmune diseases [1] Group 2: Market Context - Currently, there are no approved VAV1-targeted drugs available in the global market [1] - The potential applications of ICP-538 include treatment for inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS) [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Hangzhou Bangshun Pharmaceutical Co., Ltd. 杭州邦順製藥股份有限公司 (the "Company") (A joint stock company established in the P ...

Core Viewpoint - The announcement highlights the initiation of a Phase I/II clinical trial for HP-001 capsules, a novel oral CRBN-based molecular degrader, in combination with dexamethasone for treating relapsed/refractory multiple myeloma patients [1] Group 1: Product Development - HP-001 capsules are a new type of oral CRBN-based molecular degrader designed to selectively recruit and degrade transcription factors IKZF1/3, thereby activating anti-tumor responses [1] - Preclinical studies indicate that HP-001 capsules demonstrate superior degradation efficacy and selectivity compared to approved IMiDs and next-generation candidates, with a higher affinity for CRBN [1] Group 2: Clinical Trial Progress - The first subject has been dosed in the clinical trial, marking a significant milestone in the development of HP-001 capsules [1] - The trial aims to evaluate the safety and efficacy of HP-001 in overcoming resistance mechanisms while minimizing on-target and off-target toxicity [1]